Adaptin Bio (APTN) Notes Payables (2022 - 2024)
Adaptin Bio's (APTN) quarterly Notes Payables came in at $544957.0 in Q4 2024, up 570.97% year-over-year from $81219.0 in Q1 2024, and up 295.57% quarter-over-quarter from $137764.0 in Q3 2024.
Analysis
Adaptin Bio (APTN) Notes Payables (2022 - 2024) Analysis & Trends
Adaptin Bio has disclosed Notes Payables across 3 years of filings, most recently posting $544957.0 for Q4 2024.
- In Q4 2024, Notes Payables rose 570.97% year-over-year to $544957.0; the TTM figure through Dec 2024 stood at $544957.0 (up 570.97% YoY), while the FY2024 annual figure was $544957.0, up 570.97% from the prior year.
- Notes Payables came in at $544957.0 for Q4 2024 at Adaptin Bio, up from $137764.0 in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $544957.0 in Q4 2024 to a low of $304.0 in Q4 2022.
- Average Notes Payables over 3 years is $140129.6, with a median of $81219.0 recorded in 2023.
- Year-over-year, Notes Payables jumped 26616.78% in 2023 and soared 502.33% in 2024.
- Over 3 years, Notes Payables stood at $304.0 in 2022, then jumped by 26616.78% to $81219.0 in 2023, then soared by 570.97% to $544957.0 in 2024.
- Per Business Quant data, the three most recent Notes Payables figures were $544957.0 in Q4 2024, $137764.0 in Q3 2024, and $112572.0 in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Adaptin Bio | 56.76 Mn | 56.09 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 544,957.00 |
| Sep 30, 2024 | 137,764.00 |
| Jun 30, 2024 | 112,572.00 |
| Mar 31, 2024 | 81,219.00 |
| Dec 31, 2023 | 81,219.00 |
| Sep 30, 2023 | 22,872.00 |
| Dec 31, 2022 | 304.00 |